Exagen(US:XGN) Globenewswire·2025-10-21 20:05Core Insights - Exagen Inc. will release its financial results for Q3 2025 on November 4, 2025, before market opening [1] - The conference call to discuss the results will be hosted by the President and CEO, John Aballi, along with CFO Jeff Black at 8:30 a.m. ET [1] Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on transforming care for patients with chronic autoimmune conditions [2] - The company's flagship product, AVISE CTD, aids in the early and accurate diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [2] - Exagen operates a CLIA-certified, CAP-accredited laboratory specializing in rheumatic disease testing, providing precise and timely results [2] - The company emphasizes research, innovation, education, and patient-centered care to address challenges in autoimmune disease management [2]